Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.30B
Revenue (ttm)	1.07B
Net Income (ttm)	621.98M
Shares Out	n/a
EPS (ttm)	0.81
PE Ratio	8.52
Forward PE	n/a
Dividend	0.23 (7.66%)
Ex-Dividend Date	Jun 25, 2025

Volume	14,400
Average Volume	205,105
Open	2.940
Previous Close	2.940
Day's Range	2.910 - 2.960
52-Week Range	1.990 - 3.130
Beta	n/a
RSI	54.53
Earnings Date	Oct 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY